These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

799 related items for PubMed ID: 17199293

  • 41. Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein.
    Yin H, Hamilton AD.
    Bioorg Med Chem Lett; 2004 Mar 22; 14(6):1375-9. PubMed ID: 15006365
    [Abstract] [Full Text] [Related]

  • 42. Amino acid requirement for the high affinity binding of a selected arginine-rich peptide with the HIV Rev-response element RNA.
    Sugaya M, Nishino N, Katoh A, Harada K.
    J Pept Sci; 2008 Aug 22; 14(8):924-35. PubMed ID: 18351707
    [Abstract] [Full Text] [Related]

  • 43. The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl.
    Xu H, Tai J, Ye H, Kang CB, Yoon HS.
    Biochem Biophys Res Commun; 2006 Mar 24; 341(4):938-44. PubMed ID: 16455050
    [Abstract] [Full Text] [Related]

  • 44. Bh3 induced conformational changes in Bcl-Xl revealed by crystal structure and comparative analysis.
    Rajan S, Choi M, Baek K, Yoon HS.
    Proteins; 2015 Jul 24; 83(7):1262-72. PubMed ID: 25907960
    [Abstract] [Full Text] [Related]

  • 45. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.
    Mukherjee P, Desai P, Zhou YD, Avery M.
    J Chem Inf Model; 2010 May 24; 50(5):906-23. PubMed ID: 20392095
    [Abstract] [Full Text] [Related]

  • 46. Delivery of Bcl-XL or its BH4 domain by protein transduction inhibits apoptosis in human islets.
    Klein D, Ribeiro MM, Mendoza V, Jayaraman S, Kenyon NS, Pileggi A, Molano RD, Inverardi L, Ricordi C, Pastori RL.
    Biochem Biophys Res Commun; 2004 Oct 15; 323(2):473-8. PubMed ID: 15369775
    [Abstract] [Full Text] [Related]

  • 47. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein.
    Han Z, Simpson JT, Fivash MJ, Fisher R, Mori T.
    Peptides; 2004 Apr 15; 25(4):551-61. PubMed ID: 15165709
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
    Lee MS, Ha JH, Yoon HS, Lee CK, Chi SW.
    Biochem Biophys Res Commun; 2014 Feb 28; 445(1):120-5. PubMed ID: 24491548
    [Abstract] [Full Text] [Related]

  • 52. The anti-apoptotic molecules Bcl-xL and Bcl-w target protein phosphatase 1alpha to Bad.
    Ayllón V, Cayla X, García A, Fleischer A, Rebollo A.
    Eur J Immunol; 2002 Jul 28; 32(7):1847-55. PubMed ID: 12115603
    [Abstract] [Full Text] [Related]

  • 53. Heat-induced dimerization of BCL-xL through alpha-helix swapping.
    Denisov AY, Sprules T, Fraser J, Kozlov G, Gehring K.
    Biochemistry; 2007 Jan 23; 46(3):734-40. PubMed ID: 17223694
    [Abstract] [Full Text] [Related]

  • 54. Rational design, analysis, and potential utility of GM-CSF antagonists.
    Monfardini C, Kieber-Emmons T, VonFeldt JM, Godillot AP, Voet D, Weiner DB, Williams WV.
    Proc Assoc Am Physicians; 1996 Nov 23; 108(6):420-31. PubMed ID: 8956365
    [Abstract] [Full Text] [Related]

  • 55. mRNA display selection of a high-affinity, Bcl-X(L)-specific binding peptide.
    Matsumura N, Tsuji T, Sumida T, Kokubo M, Onimaru M, Doi N, Takashima H, Miyamoto-Sato E, Yanagawa H.
    FASEB J; 2010 Jul 23; 24(7):2201-10. PubMed ID: 20181936
    [Abstract] [Full Text] [Related]

  • 56. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
    Bernardo PH, Wan KF, Sivaraman T, Xu J, Moore FK, Hung AW, Mok HY, Yu VC, Chai CL.
    J Med Chem; 2008 Nov 13; 51(21):6699-710. PubMed ID: 18925736
    [Abstract] [Full Text] [Related]

  • 57. Fusion of the tetanus toxin C fragment binding domain and Bcl-xL for protection of peripheral nerve neurons.
    Carlton E, Teng Q, Federici T, Yang J, Riley J, Boulis NM.
    Neurosurgery; 2008 Dec 13; 63(6):1175-82; discussion 1182-4. PubMed ID: 19057331
    [Abstract] [Full Text] [Related]

  • 58. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins.
    Wu JS, Lin TN, Wu KK.
    J Cell Physiol; 2009 Jul 13; 220(1):58-71. PubMed ID: 19229877
    [Abstract] [Full Text] [Related]

  • 59. Structure-based mechanism of ligand binding for periplasmic solute-binding protein of the Bug family.
    Herrou J, Bompard C, Antoine R, Leroy A, Rucktooa P, Hot D, Huvent I, Locht C, Villeret V, Jacob-Dubuisson F.
    J Mol Biol; 2007 Nov 02; 373(4):954-64. PubMed ID: 17870093
    [Abstract] [Full Text] [Related]

  • 60. The cell death machinery controlled by Bax and Bcl-XL is evolutionarily conserved in Ciona intestinalis.
    Takada N, Yamaguchi H, Shida K, Terajima D, Satou Y, Kasuya A, Satoh N, Satake M, Wang HG.
    Apoptosis; 2005 Dec 02; 10(6):1211-20. PubMed ID: 16215691
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.